The prevention, diagnosis, and management of infectious disease in transplantation are
major contributors to improved outcomes in organ transplantation. The risk of serious …

Adoptive immunotherapy using B-cell–targeted chimeric antigen receptor (CAR)-modified T
cells to treat hematologic malignancies is transforming cancer care for patients with …

Successful solid organ transplantation reflects meticulous attention to the details of
immunosuppression, balancing risks for graft rejection against risks for infection. The “net …

Secondary hypogammaglobulinemia (SHG) is characterized by reduced immunoglobulin
levels due to acquired causes of decreased antibody production or increased antibody loss …

Antibody deficiency or hypogammaglobulinemia can have primary or secondary etiologies.
Primary antibody deficiency (PAD) is the result of intrinsic genetic defects, whereas …

Cryptosporidium is a protozoan that infects a wide variety of vertebrates, including humans,
causing acute gastroenteritis. The disease manifests with abdominal pain and diarrhea …

The development and regulatory approval of chimeric antigen receptor T cell (CAR-T)
therapies targeting the B-lineage surface antigen CD19 represents a major milestone in …

Immunoglobulin (Ig) replacement therapy dramatically changed the clinical course of
primary hypogammaglobulinemias, significantly reducing the incidence of infectious events …

abstract Solid-organ transplantation (SOT) has become the preferred strategy to treat a
number of end-stage organ disease, because a continuous improvement in survival and …

Infectious complications remain a leading cause of morbidity and mortality after solid organ
transplantation (SOT), and largely depend on the net state of immunosuppression achieved …